These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29380350)

  • 21. Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.
    Knöpfel N; Martín-Santiago A; Bauza A; Hervás JA
    Actas Dermosifiliogr; 2014 Oct; 105(8):802-3. PubMed ID: 24355193
    [No Abstract]   [Full Text] [Related]  

  • 22. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol.
    DeKlotz CM; Ogram AE; Singh S; Dronavalli S; MacGregor JL
    Arch Dermatol; 2011 Sep; 147(9):1116-7. PubMed ID: 21931059
    [No Abstract]   [Full Text] [Related]  

  • 23. A Review of Topical Sirolimus for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex.
    Dao DD; Pixley JN; Akkurt ZM; Feldman SR
    Ann Pharmacother; 2024 Apr; 58(4):428-433. PubMed ID: 37386842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Successful treatment of facial angiofibromas with local sirolimus in childhood in Bourneville-Pringle disease].
    Bottyán K; Kemény L; Csoma ZR
    Orv Hetil; 2019 Mar; 160(13):516-520. PubMed ID: 30907099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topical rapamycin combined with calcitriol in treating angiofibromas in tuberous sclerosis complex.
    Lee CH
    Br J Dermatol; 2020 Oct; 183(4):604-606. PubMed ID: 32338383
    [No Abstract]   [Full Text] [Related]  

  • 26. Validation of the Index for Facial Angiofibromas: A new scoring tool to assess facial angiofibromas in the tuberous sclerosis complex.
    Dill PE; Bessis D; Guidi B; Hadj-Rabia S; Itin P; Koenig MK; Moreno-Artero E; Erlanger TE; Cattaneo M; Weber P; Wataya-Kaneda M
    J Am Acad Dermatol; 2022 Dec; 87(6):1448-1450. PubMed ID: 35940368
    [No Abstract]   [Full Text] [Related]  

  • 27. A survey of patients with facial angiofibromas associated with tuberous sclerosis complex: Short-, medium- and long-term efficacy and safety of topical rapamycin.
    Sigg N; Fouquet J; Morin D; Farges D; Vrignaud S; Martin L
    Ann Dermatol Venereol; 2023 Dec; 150(4):270-273. PubMed ID: 37821253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient.
    Micozkadioglu H; Koc Z; Ozelsancak R; Yildiz I
    Ren Fail; 2010; 32(10):1233-6. PubMed ID: 20954988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ambient-stable topical rapamycin cream is effective in treating angiofibromas in tuberous sclerosis complex.
    Hong CH; Lee CH
    Br J Dermatol; 2023 Oct; 189(5):507-508. PubMed ID: 37672663
    [No Abstract]   [Full Text] [Related]  

  • 30. [Topical sirolimus 0.4% formulation for treatment of facial angiofibromas].
    Cuevas Asencio I; Albornoz López R; Salido Vallejo R; Reyes Malia M
    Farm Hosp; 2012; 36(5):433-4. PubMed ID: 22858090
    [No Abstract]   [Full Text] [Related]  

  • 31. Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence.
    Cortell Fuster C; Martínez Gómez MA; Cercós Lleti AC; Climente Martí M
    J Dermatolog Treat; 2022 Jun; 33(4):1804-1810. PubMed ID: 33821748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Photodynamic therapy in a patient with facial angiofibromas due to tuberous sclerosis complex.
    Shi M; He S; Chen P; Li Q; Zhu M; Guo J; Jiang L; Wang Q; Peng X; Li S; Li C; Zeng K
    Photodiagnosis Photodyn Ther; 2019 Dec; 28():183-185. PubMed ID: 31398516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acneiform Lesion: Importance of Detailed Skin Examination.
    Samanta D
    Indian J Pediatr; 2016 May; 83(5):485-6. PubMed ID: 26558921
    [No Abstract]   [Full Text] [Related]  

  • 34. Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions.
    Tu J; Foster RS; Bint LJ; Halbert AR
    Australas J Dermatol; 2014 Feb; 55(1):63-9. PubMed ID: 24359523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unilateral multiple facial angiofibromas: a mosaic form of tuberous sclerosis.
    Silvestre JF; Bañuls J; Ramón R; Guijarro J; Botella R; Betlloch I
    J Am Acad Dermatol; 2000 Jul; 43(1 Pt 1):127-9. PubMed ID: 10863238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Multiple and unilateral angiofibromas of the face: forme fruste of Bourneville tuberous sclerosis].
    García Muret MP; Pujol RM; de Moragas JM
    Ann Dermatol Venereol; 1998 May; 125(5):325-7. PubMed ID: 9747280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted topical and combination laser surgery for the treatment of angiofibromas.
    Bae-Harboe YS; Geronemus RG
    Lasers Surg Med; 2013 Nov; 45(9):555-7. PubMed ID: 24136238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients.
    Foster RS; Bint LJ; Halbert AR
    Australas J Dermatol; 2012 Feb; 53(1):52-6. PubMed ID: 22309333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of angiofibromas in tuberous sclerosis complex: the effect of topical rapamycin and concomitant laser therapy.
    Park J; Yun SK; Cho YS; Song KH; Kim HU
    Dermatology; 2014; 228(1):37-41. PubMed ID: 24401865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response.
    Truchuelo T; Díaz-Ley B; Ríos L; Alcántara J; Jaén P
    Dermatol Online J; 2012 Jan; 18(1):15. PubMed ID: 22301052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.